| 刘梅 张幸平 甘露 张涛 戴晓波 徐舒曼.厄洛替尼治疗19例晚期非小细胞肺癌的临床观察[J].,2016,16(20):3876-3879 |
| 厄洛替尼治疗19例晚期非小细胞肺癌的临床观察 |
| Clinical Observation for 19 Cases of Advanced Non-small-cell Lung CancerTreated with Erlotinib |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 分子靶向治疗 表皮生长因子受体 酪氨酸激酶抑制剂 厄洛替尼 |
| 英文关键词: Non-small-cell lung cancer Molecular targeted therapy Epidermal growth factor receptor Tyrosine kinase inhibitor Erlotinib |
| 基金项目:国家临床重点专科建设项目经费资助（国卫办医函[2013]544 号） |
|
| 摘要点击次数: 823 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：观察厄洛替尼（Erlotinib）治疗晚期非小细胞肺癌（non-small-cell lung cancer，NSCLC）的临床疗效及毒副反应。方法：我
科于2011 年2 月-2014 年2 月收治19 例晚期NSCLC 患者，给予口服Erlotinib 150 mg/ 天进行分子靶向治疗，直至疾病进展或
出现不可耐受的毒副反应，对其临床疗效及毒副反应进行观察。结果：19 例患者均可进行疗效评估，客观缓解率为21.1 %（4/19），
疾病控制率为63.2 %（12/19）。中位无进展生存期为8 个月（95 %CI 5.5-10.8），中位生存期为17个月（95 %CI 11.3-22.7），1 年生存
率为73.7 %（14/19），2 年生存率为45.5 %（5/11）。分析发现患者的性别、年龄、病理类型、吸烟史、手术史、放疗史与客观缓解率、疾
病控制率无明显相关性（P＞0.05），仅化疗史与疾病控制率相关（P=0.02）。Erlotinib 的副反应较轻，无患者因毒副反应而减量或停
药。结论：Erlotinib 治疗晚期NSCLC 的疗效及安全性良好，可作为不能耐受放化疗或放化疗失败的晚期NSCLC 患者的治疗选
择。 |
| 英文摘要: |
| Objective:To observe the efficacy and adverse events of Erlotinib in treatment of advanced non-small-cell lung cancer
（NSCLC）.Methods:From February 2011 to February 2014, 19 cases of advanced NSCLC patients were treated with Erlotinib orally, at
a dose of 150 mg per day till disease progression or intolerable adverse events. The efficacy and adverse events of Erlotinib was detected.Results:Among 19 evaluable cases, the objective response rate（ORR）was 21.1 %(4/19) and the disease control rate（DCR）was 63.2 %
(12/19). The median progression free survival（PFS）was 8 months, and the median overall survival（OS）was 17 months. 1-year survival
rate was 73.7 %(14/19), 2-year survival rate was 45.5 %（5/11）. Analysis showed that gender, age, pathological type, smoking history,
surgery, radiotherapy had little correlation on the objective response rate, disease control rate （P＞0.05）. Only chemotherapy was
associated with disease control rate（P=0.02）. The side -effect of Erlotinib was mild, no dose reduction or withdrawal of drugs in all the
patients due to adverse reaction.Conclusion:Erlotinib is effective and safety for advanced NSCLC, it is a good choice for advanced
NSCLC patients who can not tolerate chemoradiotherapy or chemoradiotherapy failure. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
